H.C. Wainwright Sticks to Their Buy Rating for LB Pharmaceuticals, Inc. (LBRX)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on LB Pharmaceuticals, Inc., with a price target of $45.00.

Introducing TipRanks MCP for Agents

Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Selvaraju covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Aclaris Therapeutics, and Urogen Pharma. According to TipRanks, Selvaraju has an average return of 18.4% and a 50.10% success rate on recommended stocks.

Currently, the analyst consensus on LB Pharmaceuticals, Inc. is a Strong Buy with an average price target of $46.83.

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on LB Pharmaceuticals (LBRX) with a $45 price target. The broader analyst consensus for LBRX is Strong Buy, with an average price target of $46.83.

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on LB Pharmaceuticals, Inc., with a price target of $45.00.

Introducing TipRanks MCP for Agents

Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Currently, the analyst consensus on LB Pharmaceuticals, Inc. is a Strong Buy with an average price target of $46.83.